Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001387618 | SCV001588290 | pathogenic | Granulomatous disease, chronic, X-linked | 2020-02-27 | criteria provided, single submitter | clinical testing | Donor and acceptor splice site variants typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CYBB are known to be pathogenic (PMID: 9585602, 20729109). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. Variants at this acceptor site have been observed in individual(s) with chronic granulomatous disease(PMID: 11162142, 1520880). This variant is not present in population databases (ExAC no frequency). This sequence change affects an acceptor splice site in intron 1 of the CYBB gene. It is expected to disrupt RNA splicing and likely results in an absent or disrupted protein product. For these reasons, this variant has been classified as Pathogenic. |
Genome |
RCV001387618 | SCV001749843 | not provided | Granulomatous disease, chronic, X-linked | no assertion provided | phenotyping only | Variant interpreted as Pathogenic and reported on 03-08-2020 by Invitae. GenomeConnect-Invitae Patient Insights Network assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. Registry team members make no attempt to reinterpret the clinical significance of the variant. Phenotypic details are available under supporting information. |